Email ID
Password
Scrip   
PARP inhibitors for breast cancer take centre stage at ASCO
05 June 2009
Malini Guha

A new class of anticancer drug, the PARP inhibitors, took centre stage at the ASCO meeting in Orlando after Phase II studies revealed their promise in specific subtypes of breast and ovarian cancer.

BiPar Sciences' PARP inhibitor BSI-201 resulted in a high response rate and improved...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36